MCM
SUPN icon

McGlinn Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

McGlinn Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-30,300
Closed -$228K – 66
2013
Q4 		$228K Sell
30,300
-11,400
-27% -$79.7K 0.52% 44
2013
Q3 		$306K Sell
41,700
-13,000
-24% -$87.3K 0.75% 36
2013
Q2 		$352K Buy
+54,700
New +$322K 0.96% 33

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
MOACM
Mutual of America Capital Management New York $8.8B AUM 29.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

McGlinn Capital Management's SUPN Position: Q1 2014 in Review

McGlinn Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2014, closing a stake of 30,300 shares — an estimated $228K sold.

McGlinn Capital Management first reported a position in SUPN in Q2 2013 and held it in 3 quarters. The position peaked at $352K in Q2 2013. 83 funds tracked by Wall St. Rank hold SUPN as of Q1 2014.

  • McGlinn Capital Management reported no remaining Supernus Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • McGlinn Capital Management sold 30,300 Supernus Pharmaceuticals shares in Q1 2014, an estimated $228K.
  • McGlinn Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • McGlinn Capital Management's Supernus Pharmaceuticals position peaked at $352K in Q2 2013.
  • 83 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2014.

Based on McGlinn Capital Management's 13F filing for Q1 2014, filed 9 May 2014.